GlaxoSmithKline Pharmaceuticals Limited
Prices are adjusted according to historical splits.
- Today's Low:
- Today's High:
- Open Price:
- 52W Low:
- 52W High:
- Prev. Close:
- Market Cap.:
- ₹221.31 billion
- Book Value:
- Revenue TTM:
- ₹32.52 billion
- Operating Margin TTM:
- Gross Profit TTM:
- ₹18.99 billion
- Profit Margin:
- Return on Assets TTM:
- Return on Equity TTM:
GlaxoSmithKline Pharmaceuticals Limited had its IPO on under the ticker symbol GLAXO.
The company operates in the Healthcare sector and Drug Manufacturers-General industry. GlaxoSmithKline Pharmaceuticals Limited has a staff strength of 0 employees.
Shares of GlaxoSmithKline Pharmaceuticals Limited opened at ₹1311 at the start of the last trading session i.e. 2023-05-28.
The stocks traded within a range of ₹1300 - ₹1311, and closed at ₹1309.
This is a +0.35% increase from the previous day's closing price.
A total volume of 16,988 shares were traded at the close of the day’s session.
In the last one week, shares of GlaxoSmithKline Pharmaceuticals Limited have increased by +2.15%.
GlaxoSmithKline Pharmaceuticals Limited's Key Ratios
GlaxoSmithKline Pharmaceuticals Limited has a market cap of ₹221.31 billion, indicating a price to book ratio of 15.5061 and a price to sales ratio of 6.8614.
In the last 12-months GlaxoSmithKline Pharmaceuticals Limited’s revenue was ₹32.52 billion with a gross profit of ₹18.99 billion and an EBITDA of ₹8.04 billion. The EBITDA ratio measures GlaxoSmithKline Pharmaceuticals Limited's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, GlaxoSmithKline Pharmaceuticals Limited’s operating margin was 22.71% while its return on assets stood at 11.6% with a return of equity of 27.59%.
In Q4, GlaxoSmithKline Pharmaceuticals Limited’s quarterly earnings growth was a negative -89.1% while revenue growth was a negative 2.7%.
GlaxoSmithKline Pharmaceuticals Limited’s PE and PEG Ratio
- Forward PE
- Trailing PE
Its diluted EPS in the last 12-months stands at ₹24.82 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into GlaxoSmithKline Pharmaceuticals Limited’s profitability.
GlaxoSmithKline Pharmaceuticals Limited stock is trading at a EV to sales ratio of 6.4569 and a EV to EBITDA ratio of 24.4241. Its price to sales ratio in the trailing 12-months stood at 6.8614.
GlaxoSmithKline Pharmaceuticals Limited stock pays annual dividends of ₹32 per share, indicating a yield of 2.3% and a payout ratio of 2.5%.
Balance sheet and cash flow metrics
- Total Assets
- ₹30.15 billion
- Total Liabilities
- ₹12.95 billion
- Operating Cash Flow
- Capital Expenditure
- Dividend Payout Ratio
GlaxoSmithKline Pharmaceuticals Limited ended 2023 with ₹30.15 billion in total assets and ₹0 in total liabilities. Its intangible assets were valued at ₹30.15 billion while shareholder equity stood at ₹14.55 billion.
GlaxoSmithKline Pharmaceuticals Limited ended 2023 with ₹0 in deferred long-term liabilities, ₹12.95 billion in other current liabilities, in common stock, ₹0 in retained earnings and ₹0 in goodwill. Its cash balance stood at ₹556.90 million and cash and short-term investments were ₹0. The company’s total short-term debt was ₹0 while long-term debt stood at ₹0.
GlaxoSmithKline Pharmaceuticals Limited’s total current assets stands at ₹21.95 billion while long-term investments were ₹0 and short-term investments were ₹13.00 billion. Its net receivables were ₹1.66 billion compared to accounts payable of ₹4.70 billion and inventory worth ₹6.46 billion.
In 2023, GlaxoSmithKline Pharmaceuticals Limited's operating cash flow was ₹0 while its capital expenditure stood at ₹0.
Comparatively, GlaxoSmithKline Pharmaceuticals Limited paid ₹0.03 in dividends in 2023.
Other key metrics
- Current Trading Price
- 52-Week High
- 52-Week Low
- Analyst Target Price
GlaxoSmithKline Pharmaceuticals Limited stock is currently trading at ₹1309 per share. It touched a 52-week high of ₹1528 and a 52-week low of ₹1528. Analysts tracking the stock have a 12-month average target price of ₹.
Its 50-day moving average was ₹1275.03 and 200-day moving average was ₹1331.5 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 7557.1% of the company’s stock are held by insiders while 1080.4% are held by institutions.
Frequently Asked Questions About GlaxoSmithKline Pharmaceuticals Limited
Similar Industry Stocks (Drug Manufacturers-General)
GlaxoSmithKline Pharmaceuticals Limited, a healthcare company, researches, develops, manufactures, and sells pharmaceutical medicines and vaccines in India and internationally. The company offers prescription and non-prescription drugs for anti-infective, respiratory, dermatology, nutrition, gastrointestinal, and rare diseases; and consumer healthcare products. It provides its product under the Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, T-bact, Tenovate, Flutivate, Physiogel, Zimig, Cobadex CZS, Infanrix Hexa, Synflorix, Supacef, Havrix, Menveo, Boostrix, Fluarix Tetra, Varilrix, Nucala, and Trelegy Ellipta brands. The company was formerly known as SmithKline Beecham Pharmaceuticals India Ltd. and changed its name to GlaxoSmithKline Pharmaceuticals Limited in 2001. GlaxoSmithKline Pharmaceuticals Limited was incorporated in 1924 and is headquartered in Mumbai, India.